CAMP4 Therapeutics Targets First SYNGAP1 Data in 2028 as Patient Dosing Nears
CAMP4 Therapeutics plans to start patient dosing for its SYNGAP1 treatment, CMP-002, by year-end and report initial data in early 2028. The Phase 1/2 trial will evaluate safety and potential efficacy signals, but not establish efficacy. The company has $124.5 million in cash, expected to fund operations through 2028, including the SYNGAP1 readout and other programs.
How this was made

The 30-second read
Why it matters
The announcement sets a timeline for first patient dosing and data readout, which could drive short‑term interest.
Market read
Early trial milestones are material for micro‑cap biotech investors but limited in broader market scope.
What to watch
Potential competition in SYNGAP1 space and reliance on cash runway.
Background
CAMP4 Therapeutics is a clinical‑stage biotech focusing on neurodevelopmental disorders.
Market effects
Adds to the pipeline momentum for rare‑disease biotech sector.
Limited to US biotech investors.
Minimal global impact.
Counterpoint
Data may be delayed or fail to show efficacy, causing a sell‑off.
Key entities
- companyCAMP4 Therapeutics
Biotech developing SYNGAP1 and SHANK3 therapies.
